Skip to content

Study · Not a test of the peptide alone · 2002

1 result

Determination of melanotan-II in rat plasma by liquid chromatography/tandem mass spectrometry: determination of pharmacokinetic parameters in rat following intravenous administration.

Mock S, Shen X, Tamvakopoulos C

Rapid communications in mass spectrometry : RCM1 Jan 2002Cited by 10 (Europe PMC)

PMID12415547 (opens in a new tab)DOI10.1002/rcm.847 (opens in a new tab)PepBankPUB-12415547
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan II.

  1. 01AnimalNot a test of Melanotan II aloneAnimal study (in vivo)Other

    A liquid chromatography/tandem mass spectrometry method quantified melanotan II in rat plasma with a limit of quantitation of 5 ng/mL.

    In plain wordsIn rat plasma, a laboratory method could measure melanotan II down to 5 ng/mL.

    Peptide
    Melanotan II
    Outcome
    Not applicableLC/MS/MS assay limit of quantitation in rat plasma
    Study

    ratn: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Measurements

    Limit of quantitation
    5 ng/mL
    rat plasma

    Source sentences

    Summary
    Using the described approach a limit of quantitation of 5 ng/mL was achieved in rat plasma.

    In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.